A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)
- Registration Number
- NCT00290550
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Patients who are at least 18 years of age with cancer of the lung and who have had either no previous treatment or 1 previous treatment for advanced cancer of the lung. Certain other treatments may also be allowed (prior cytotoxic chemotherapy in the adjuvant setting)
Exclusion Criteria
- Patients who have had treatment with any investigational therapy within the past 30 days are not eligible.
- Patients who have had a disease or medical condition that is not controlled will not be eligible.
- Patients who are pregnant or breastfeeding are not eligible.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 MK0457 MK-0457
- Primary Outcome Measures
Name Time Method Efficacy of MK0457 as a 5 day infusion as measured by radiological exams at baseline and after every other cycle of treatment. After 3 post-treatment radiological assessments, response will be measured after every third cycle. 5 Days
- Secondary Outcome Measures
Name Time Method Safety and tolerability as measured by duration, intensity (grade) and time of onset of toxicity. 5 Days